Biotechnology Companies in Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery. The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.

We brings precise microencapsulation at industrial scale: Microcaps developed a novel technology that enables the scalable production of precise microcapsules and microparticles based on microfluidics. With this invention, microcaps is able to increase the controlled production by a factor of 1000 compared to state-of-the-art technologies. Our goal is to provide an upscalable, fully-automated encapsulation micro-factory, that enables size control, precise dosing and increased stability of the microcapsules and microparticles.

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.

#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

Saphetor SA, is a global precision-medicine company dedicated to large-scale identification and interpretation of human genetic variants by leveraging proprietary algorithms and expert domain knowledge. Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions for clinicians and researchers. VarSome is powered by a Molecular DB with over 130 integrated and harmonized genomic data sources, linked by AI to over 32 million publications. Thanks to VarSome’s global community of over 450 000, the database is further enriched by additional unique user-generated annotation. Saphetor has developed proprietary algorithms to automate variant classification based on industry-standard ACMG and AMP guidelines for interpretation of germline and somatic variants, as well as CNVs. The VarSome suite offers solutions for individuals needing a powerful Search tool to support research, professional labs requiring a CE-IVD and HIPPA-compliant platform to Analyze NGS samples, and bioinformaticians wanting to use our simple API to access our database and classifiers and integrate into existing Code.

Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics.

About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company attracts talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and virology. The company conducts research and development both internally and in partnerships with leading pharmaceutical companies and is backed by top biotech investors.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

rqmicro AG, based in Zurich, Switzerland, develops and markets proprietary reagents and innovative instruments for rapid microbiological tests for water and food safety. The new separation and detection technology is based on immunomagnetic separation and microfluidics and delivers accurate results at an unmatched speed. Common methods in microbiology need up to 14 days to give you semi-quantitative data. A waiting time that takes time and money. rqmicro reduces this delay significantly by providing precise quantitative results. With rqmicro. COUNT you can rapidly quantify specific pathogenic bacteria, such as Legionella and E. coli, or the total number of bacteria in water samples in up to 2 hours after taking samples. Discover more about rqmicro.COUNT. Visit our website: www.rqmicro.com

is a preclinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders.

Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.

Timeline (parent company Amazentis) is an innovative, dynamic and growing biotech company positioned in the nutrition and skin health sectors and is located in the multicultural region of Lausanne, Switzerland. Acting at the intersection of the food and pharma industries, Amazentis employs best-in-class science to discover and develop new products to increase longevity, manage specific health needs, and support an active lifestyle.

Biolux Medical is biotechnology company that specializes in photomodulation.

Bionomous combines innovative micro-engineering design and artificial intelligence to automatically inspect and sort miniature biological entities. Our technology was originally developed to handle the eggs of zebrafish (Danio rerio), but it can handle any round entity ranging from 0.6 to 1.5 mm. It has been used to sort xenopus oocytes and embryos, killifish eggs, and even seeds!

Recolony is a Swiss biotech start-up with the goal of developing a bacteria-based oral therapy to treat and prevent cancer.

Demiurge pioneers high-accuracy MoA-based prediction of clinical trial outcomes. * Posts here are for information only without any warranty of any kind.

Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/

GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.

MaxiVAX SA is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immuno-therapy. Its treatment is capable of stimulating the natural immune response of the patient to eliminate cancer cells. Phase I clinical trials were completed with no safety issue, were well tolerated and with encouraging efficacy data. The company received the 2017 CTI Swiss Medtech Award for its ground-breaking work, and its lead product, MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland. The company successfully filed an IND with the US FDA in 2018.

Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey. At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancer drug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development. Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners. This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.

Founded in 1997, Genedata delivers enterprise solutions to enable Biopharma R&D globally to discover, develop, and manufacture innovative biotherapeutics faster and more efficiently. Genedata combines computational, scientific, and technical expertise with extensive biopharma R&D domain knowledge to deliver user-friendly solutions that are scalable, open, and aligned with industry processes. Today, most of the leading pharmaceutical, biotechnology, and agrichemical companies, as well as innovative life science research institutions rely on Genedata. Genedata is proud to be part of Danaher. Danaher’s science and technology leadership puts Genedata’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

High throughput RNA sequencing, made easy.

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.